Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MedTech-related health technology assessments from NIHR in October 2023

The National Institute for Health and Care Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance. 

In October 2023, NIHR released an assessment of posterior cervical foraminotomy versus anterior cervical discectomy for cervical brachialgia. The assessment was based on the Phase III, unblinded, prospective, United Kingdom multicenter, parallel-group, individually randomized controlled superiority trial (FORVAD RCT). The target recruitment was 252 participants. However, the trial recruited slowly and closed early (after randomizing 23 participants). Consequently, the trial is underpowered, and definitive conclusions cannot be drawn. A large prospective multicenter trial comparing anterior cervical discectomy and posterior cervical foraminotomy in the treatment of cervical brachialgia is still needed.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.